GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Structure Therapeutics Inc (NAS:GPCR) » Definitions » EV-to-EBIT

GPCR (Structure Therapeutics) EV-to-EBIT : -10.15 (As of Oct. 31, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Structure Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Structure Therapeutics's Enterprise Value is $1,243.02 Mil. Structure Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-122.47 Mil. Therefore, Structure Therapeutics's EV-to-EBIT for today is -10.15.

The historical rank and industry rank for Structure Therapeutics's EV-to-EBIT or its related term are showing as below:

GPCR' s EV-to-EBIT Range Over the Past 10 Years
Min: -74.71   Med: 0   Max: 7.72
Current: -10.15

During the past 4 years, the highest EV-to-EBIT of Structure Therapeutics was 7.72. The lowest was -74.71. And the median was 0.00.

GPCR's EV-to-EBIT is ranked worse than
100% of 419 companies
in the Biotechnology industry
Industry Median: 10.01 vs GPCR: -10.15

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Structure Therapeutics's Enterprise Value for the quarter that ended in Jun. 2024 was $1,323.65 Mil. Structure Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-122.47 Mil. Structure Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -9.25%.


Structure Therapeutics EV-to-EBIT Historical Data

The historical data trend for Structure Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Structure Therapeutics EV-to-EBIT Chart

Structure Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - -13.91

Structure Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.17 -20.46 -13.91 -13.61 -10.81

Competitive Comparison of Structure Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Structure Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Structure Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Structure Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Structure Therapeutics's EV-to-EBIT falls into.



Structure Therapeutics EV-to-EBIT Calculation

Structure Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1243.015/-122.47
=-10.15

Structure Therapeutics's current Enterprise Value is $1,243.02 Mil.
Structure Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-122.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Structure Therapeutics  (NAS:GPCR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Structure Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-122.47/1323.653701
=-9.25 %

Structure Therapeutics's Enterprise Value for the quarter that ended in Jun. 2024 was $1,323.65 Mil.
Structure Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-122.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Structure Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Structure Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Structure Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
601 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Melita Sun Jung officer: Chief Business Officer C/O STRUCTURE THERAPEUTICS INC., SOUTH SAN FRANCISCO CA 94080
Yingli Ma officer: Chief Technology Officer C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD., SUITE 223, SOUTH SAN FRANCISCO CA 94080
Joanne Waldstreicher director C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080
Jun Yoon officer: Chief Financial Officer C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080

Structure Therapeutics Headlines

From GuruFocus